An observational study in Liver Transplant, Post Transplant Diabetes and Type 2 Diabetes, sponsored by Icahn School of Medicine at Mount Sinai. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.
Sponsored by Icahn School of Medicine at Mount Sinai · Observational
This investigator initiated study aims to describe continuous glucose monitoring (CGM) based glycemic metrics after discharge from liver transplant and assess relationship with glycemic metrics and liver transplant outcomes.
Liver transplant participants will be recruited. Participants will wear a blinded sensor after hospital discharge for up to 30 days. Data can be shared with participant and the providers retrospectively. Participants will be invited to wear another blinded sensor at 6 and 12 months.
10,371 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,406 are open to participants now.
This study's planned enrollment of 40 is below the median of 300 across 1,741 observational studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Icahn School of Medicine at Mount Sinai is the lead sponsor of 776 studies on the registry; 176 are open to participants now.
Of its 125 completed or terminated interventional studies of FDA-regulated products, 83 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
inpatient liver transplant participants who have had an inpatient glucose greater than 180mg/dL
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who are discharged from after liver transplant.
Device: Libre 3+
Blinded CGM will be worn by all participants
Also known as: blinded CGM
Time in range
Time in range 70-180mg/dL
Time frame: 28 days
Percent time >180mg/dL
Percent time \>180mg/dL
Time frame: 28 days
Percent time >250mg/dL
Percent time \>250mg/dL
Time frame: 28 days
Percent time <70mg/dL
Percent time \<70mg/dL
Time frame: 28 days
Percent time <54mg/dL
Percent time \<54mg/dL
Time frame: 28 days
Transplant outcomes
Rate and time to of wound complications, vascular complications, biliary complications, acute kidney injury, transplant rejection, and readmissions
Time frame: 1 year
Plan to share: No — Identifying dates
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Icahn School of Medicine at Mount Sinai →